Mr. Jack Guth, Ph.D., formerly Director of R&D at Botaneco where he was responsible for all efforts in the areas of product and process development, as well as technical service, has been appointed as Vice-President of R&D of the Corporation. Early in his career, Dr Guth held technical positions at various finished goods companies such as Gillette and Johnson and Johnson Baby Products. He then moved to the supplier side of the Personal Care business, where he held technical management positions at Inolex, National Starch, and Lonza before joining Botaneco. Active in the Personal Care area for over 35 years, he is the author of numerous articles in the areas of hair and skin care and holds approximately 20 patents. Dr Guth received his BS degree in Chemistry from the George Washington University and his PhD in Organic Chemistry from the American University.

Mr. R?©jean Drouin, who was Vice-President of R&D of the Corporation before the Transaction, will continue to lead the Advitech's R&D program as Director of R&D.

Board of Directors ------------------

The new Board of Directors consists of Louis Lacasse and Richard Bordeleau, representing AgeChem, Aki Georgacacos and Denis Boyer, representing Avrio, Claude Livernoche and Pierre Labb?©, current Board members of Advitech, and Christian Labb?©, Vice-President and Chief Financial Officer of Advitech who now joins the Board of Directors.

Mr. Lacasse is the Managing Partner of AgeChem, Mr. Bordeleau was formerly with Atrium Innovations and Biocad Medical and he is now acting as a consultant in the field of corporate development, Mr. Georgacacos is a Managing Partner of Avrio while Mr. Boyer is a Director of Avrio. Mr. Livernoche is board member of corporations and has been acting on Advitech's Board of Directors for seven years. Mr. Pierre Labb?© is Vice-President and Chief Financial Officer of Medicago, a TSX-V company (MDG), and member of Advitech's Board since May 2007.

Mr. Renaud Beauchesne, the former Executive Chairman of Advitech, has elected to retire from operations and left the Board of Directors, but he will continue to serve the Corporation as the President of the ad hoc Merger and Acquisition Committee to be created by Advitech. This Committee will also include the newly appointed President and Chief Executive Officer, Mr. Michael Stangel, Mr. Christian Labb?©, Vice President and Chief Financial Officer, Mr. Bud Kirchner, founding Partner of Avrio, and Mr. Richard Bordeleau.

Pro forma financial highlights ------------------------------

For information purposes, the financial information for the combined entities is hereunder presented on a pro forma basis, prepared by the management of Advitech and Botaneco using the financial statements of Botaneco and Advitech for the 6-month period ended June 30, 2009 and the 12-month period ended December 31, 2008, as adjusted taking into account: (i) the conversion of all Botaneco convertible debentures, (ii) the preliminary allocation of the purchase price, and (iii) the Equity Financing:

Six-month Year ended period ended Statements of Loss ($Cdn) December 31, June 30, 2008 2009 (unaudited) (unaudited) Total Revenues 1,674,899 652,589 Gross margin 379,903 15,225 Operating expenses 4,492,486 2,440,966 Amortization 791,469 421,872 Interest and exchange loss 613,368 365,399 Net Loss (5,517,420) (3,213,012) As at As at Balance sheet ($Cdn) December 31, June 30, 2008 2009 (unaudited) (unaudited) Current assets 7,471,886 5,778,513 Property and equipment 2,904,613 2,630,317 Goodwill and intangible assets 314,285 2,648,405 Current liabilities 1,632,065 1,200,569 Convertible debentures 1,620,730 26,980 Long-term debt 1,978,761 2,467,353 Shareholders' Equity 5,459,228 7,362,333 Increase of common shares available under the Corporation's Stock ----------------------------------------------------------------- Option Plan -----------

Further to the Transaction, the Equity Financing and the Redemption of the AgeChem Warrants, the Board of Directors of the Corporation has approved the increase of post-Consolidation common shares available for issuance under the Corporation's current stock option plan from 675,000 to 7,200,000 post-Consolidation common shares which represents approximately 10% of the number of post-Consolidation issued and outstanding common shares, on a post-closing basis. This increase is subject to the approval of the TSX-V.

Source: ADVITECH INC.